The Israel Antitrust Authority mergers committee is scheduled to convene on Wednesday, September 7, to set the final conditions for closing and carrying out the merger between leading supermarket chain Shufersal and New Pharm Drugstores.
A single buyer must acquire all nine branches and maintain them as a pharmacy chain, the Israel Antitrust Authority decrees.
Shufersal will have to sell 10 branches: nine branches of the New Pharm chain and one Shufersal branch with a problematic location. The branches must be sold as a single division, i.e. to one buyer, and maintained as a pharmacy chain in order to provide a platform for two competing chains —Shufersal and Super-Pharm— in addition to good infrastructure for the growth of a third chain.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
